The European Prevention of Alzheimer’s Dementia releases its first wave of data
We are delighted to announce that April was the most successful month to date with 73 new research participants enrolled in the EPAD Longitudinal Cohort Study. We continued the positive trend in recruitment of research participants by exceeding the 66 research participants enrolled in March and the 53 in February.
Congratulations are due to Université de Genève (Geneva, Switzerland) as the most successful trial delivery centre of the month screening 14 research participants in April for their inclusion in the EPAD study. According to Prof Giovanni Frisoni, principal investigator of the Geneva team: “EPAD is piloting the future. A future when Alzheimer’s will not be treated when memory symptoms are already established, but risk will be detected in the population, high risk persons will be identified and treated with drugs that will decrease the risk.”
Congratulations to the team of Giovanni Frisoni (pictured on the right) and his colleagues Frédéric Assal, Aline Mendes, Maura Parapini (second from right), Zyka Selimi (first from left), Lucas Sveitaka, Christine Trombert (third from left) and Coralie Vuilloud (second from left).
The EPAD family of trial delivery centres also grew to 15 sites in April with Hôpital Pitié Salpêtrière – AP-HP (Paris, France) and West London Mental Health (London, United Kingdom) both enrolling their first research participants.
Add to this that, in April, we reached the milestone of 600 screened research participants and we hope that you will share our positive assessment of the continuing progress of this exciting research collaboration. Stay tuned for more news in June.
Related posts
